Dr. med. Dirk Manski



 You are here: Urology Textbook > Drugs in Urology > Dutasteride


Dutasteride: Treatment of Benign Prostate Hyperplasia

Mechanism of Action of Dutasteride

Dutasteride is a selective competitive inhibitor of 5α-reductase type 1 and 2 of the prostate, seminal vesicles and skin. The inhibition lowers the concentration of dihydrotestosterone (DHT) in the prostate. Since DHT causes the androgenic effect in the prostate, the inhibition of 5α-reductase leads to a reduction in prostate volume. Furthermore, dutasteride is used to treat male pattern baldness.

Indications for Dutasteride in Urology

Dutasteride is indicated in lower urinary tract symptoms or bleeding due to benign prostate enlargement.

Pharmacokinetics of Dutasteride

Hepatic metabolization.

Side Effects of Dutasteride

Drug Interactions with Dutasteride

No important drug interactions are known.

Contraindications of Dutasteride

Dosage of Dutasteride

0,5 mg 1–0–0 p.o.







Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



References

Andriole u.a. 2004 ANDRIOLE, G. ; BRUCHOVSKY, N. ; CHUNG, L. W. ; MATSUMOTO, A. M. ; RITTMASTER, R. ; ROEHRBORN, C. ; RUSSELL, D. ; TINDALL, D.:
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
In: J Urol
172 (2004), Nr. 4 Pt 1, S. 1399–403

Chapple 2004 CHAPPLE, C. R.:
Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44


  Deutsche Version: Dutasterid